TY  - GEN
AU  - Shi,Puyu
AU  - Oh,You-Take
AU  - Zhang,Guojing
AU  - Yao,Weilong
AU  - Yue,Ping
AU  - Li,Yikun
AU  - Kanteti,Rajani
AU  - Riehm,Jacob
AU  - Salgia,Ravi
AU  - Owonikoko,Taofeek K
AU  - Ramalingam,Suresh S
AU  - Chen,Mingwei
AU  - Sun,Shi-Yong
TI  - Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
SN  - 1872-7980
PY  - 2017///0728
KW  - Acrylamides
KW  - pharmacology
KW  - Aniline Compounds
KW  - Animals
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Apoptosis
KW  - drug effects
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - Crizotinib
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - G1 Phase Cell Cycle Checkpoints
KW  - Gene Amplification
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Lung Neoplasms
KW  - Mice, Nude
KW  - Molecular Targeted Therapy
KW  - Mutation
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins c-met
KW  - genetics
KW  - Pyrazoles
KW  - Pyridines
KW  - Pyrimidines
KW  - RNA Interference
KW  - Signal Transduction
KW  - Time Factors
KW  - Transfection
KW  - Tumor Burden
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1016/j.canlet.2016.07.021
ER  -